Evolent Health (NYSE:EVH) had its price target reduced by analysts at SunTrust Banks from $16.00 to $12.00 in a research note issued to investors on Thursday, BenzingaRatingsTable reports. The firm presently has a “buy” rating on the technology company’s stock. SunTrust Banks’ target price would suggest a potential upside of 146.41% from the stock’s current price.

Several other equities analysts have also issued reports on the company. ValuEngine raised Evolent Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 4th. Wells Fargo & Co dropped their price objective on Evolent Health from $19.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $10.15 price objective on shares of Evolent Health in a report on Wednesday, December 18th. Canaccord Genuity reaffirmed a “buy” rating and set a $19.00 price objective on shares of Evolent Health in a report on Thursday, February 13th. Finally, Zacks Investment Research raised Evolent Health from a “sell” rating to a “hold” rating in a report on Thursday, March 12th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Evolent Health presently has an average rating of “Buy” and an average price target of $13.99.

Evolent Health stock traded up $0.39 during midday trading on Thursday, reaching $4.87. The company’s stock had a trading volume of 14,304 shares, compared to its average volume of 1,369,344. Evolent Health has a fifty-two week low of $3.50 and a fifty-two week high of $14.79. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.39. The company has a market cap of $380.40 million, a P/E ratio of -1.24 and a beta of 1.07. The business has a 50-day simple moving average of $8.58 and a 200-day simple moving average of $8.55.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Tuesday, February 25th. The technology company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.03). The firm had revenue of $237.51 million for the quarter, compared to analysts’ expectations of $234.08 million. Evolent Health had a negative return on equity of 6.97% and a negative net margin of 35.68%. As a group, equities analysts forecast that Evolent Health will post -0.65 earnings per share for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CFM Wealth Partners LLC purchased a new position in shares of Evolent Health during the fourth quarter worth about $42,000. Sigma Planning Corp purchased a new stake in Evolent Health in the 4th quarter valued at approximately $91,000. ProShare Advisors LLC purchased a new stake in Evolent Health in the 4th quarter valued at approximately $91,000. Cubist Systematic Strategies LLC boosted its holdings in Evolent Health by 63.2% in the 4th quarter. Cubist Systematic Strategies LLC now owns 11,100 shares of the technology company’s stock valued at $100,000 after purchasing an additional 4,300 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Evolent Health in the 4th quarter valued at approximately $105,000.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

Recommended Story: What is a Candlestick Chart?

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.